Get the Stockscreener App
35.01
1.13%
0.39
Lb Pharmaceuticals Inc stock is traded at $35.01, with a volume of 333.82K.
It is up +1.13% in the last 24 hours and up +14.86% over the past month.
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
See More
Previous Close:
$34.62
Open:
$34.89
24h Volume:
333.82K
Relative Volume:
1.35
Market Cap:
$1.00B
Revenue:
-
Net Income/Loss:
$-38.95M
P/E Ratio:
-23.56
EPS:
-1.4857
Net Cash Flow:
$-50.43M
1W Performance:
+11.46%
1M Performance:
+14.86%
6M Performance:
+46.42%
1Y Performance:
+0.00%
1-Day Range:
$34.11
$35.93
1-Week Range:
$30.49
$36.60
52-Week Range:
$13.36
$36.60
Lb Pharmaceuticals Inc Stock (LBRX) Company Profile
Name
Lb Pharmaceuticals Inc
Sector
Industry
Phone
917-450-6581
Address
575 MADISON AVENUE, NEW YORK
Compare LBRX vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LBRX
Lb Pharmaceuticals Inc
|
35.01 | 1.00B | 0 | -38.95M | -50.43M | -1.4857 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Lb Pharmaceuticals Inc Stock (LBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-26 | Initiated | H.C. Wainwright | Buy |
| Apr-10-26 | Initiated | Craig Hallum | Buy |
| Jan-09-26 | Initiated | Roth Capital | Buy |
| Oct-06-25 | Initiated | Leerink Partners | Outperform |
| Oct-06-25 | Initiated | Piper Sandler | Overweight |
| Oct-06-25 | Initiated | Stifel | Buy |
View All
Lb Pharmaceuticals Inc Stock (LBRX) Latest News
LB Pharmaceuticals Inc $LBRX is Spruce Street Capital LP's 3rd Largest Position - MarketBeat
Enterprise value to revenue forward of LB Pharmaceuticals Inc – BOATS:LBRX - TradingView
H.C. Wainwright reiterates Buy on LB Pharmaceuticals stock By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Buy on LB Pharmaceuticals stock - Investing.com
LB Pharmaceuticals: Buy Rating Reaffirmed on LB-102 Clinical Momentum and Regulatory Progress; $45 Price Target Maintained - TipRanks
LB Pharmaceuticals Inc (LBRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
LB Pharmaceuticals (NASDAQ:LBRX) Reaches New 1-Year HighTime to Buy? - MarketBeat
LB Pharmaceuticals accelerates Phase 3 schizophrenia trial timeline - TipRanks
LB Pharmaceuticals accelerates schizophrenia trial timeline By Investing.com - Investing.com South Africa
LB Pharmaceuticals accelerates schizophrenia trial timeline - Investing.com
LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia - The Manila Times
LB Pharmaceuticals Expects Results From 460-Patient Trial in 1H 2027 - Stock Titan
LB Pharmaceuticals (NASDAQ:LBRX) Upgraded by BMO Capital Markets to Strong-Buy Rating - MarketBeat
JPMorgan Chase & Co. Increases Stake in LB Pharmaceuticals Inc. - GuruFocus
Jennison Associates LLC Sells 283,636 Shares of LB Pharmaceuticals Inc $LBRX - MarketBeat
Enterprise value to EBITDA forward of LB Pharmaceuticals Inc – BOATS:LBRX - TradingView
LB PHARMACEUTICALS INC : BMO INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $46 - Bitget
LBRX Initiated Coverage by BMO Capital -- Rated Outperform at $4 - GuruFocus
Price to book forward of LB Pharmaceuticals Inc – NASDAQ:LBRX - TradingView
BMO initiates LB Pharmaceuticals stock at Outperform on drug data By Investing.com - Investing.com South Africa
BMO initiates LB Pharmaceuticals stock at Outperform on drug data - Investing.com
LB Pharmaceuticals Inc (LBRX) Gains 2.68% as Shares Approach Key Resistance at $32.98Volatility Smile - dars.gov.et
Heather Turner: LB Pharma's Schizophrenia Drug Could Go from One Trial to Approval - finance.biggo.com
LB Pharmaceuticals Inc (LBRX) Holds Near $32 as Biotech Sector Shows Mixed SignalsADD Alert - dars.gov.et
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
LBRX Q1 2026 Earnings: Narrowed Loss Beats Expectations Amid Pipeline ProgressFinancial Summary - DonanımHaber
LB Pharmaceuticals Inc (LBRX) Slides 2.34% as Technical Support Levels Come into FocusWyckoff Spring - DonanımHaber
LB Pharmaceuticals grants stock options to new SVP under Nasdaq inducement rule - Pluang
LB Pharmaceuticals Grants Inducement Equity Award to New Senior Vice President of Clinical Operations - Quiver Quantitative
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Press Release: LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
LB Pharmaceuticals Inc (LBRX) Edges Higher, Testing Key Resistance ZoneUp Down Ratio - DonanımHaber
LB Pharmaceuticals Inc (LBRX) Gains 2.63% on Above-Average Volume, Tests Key Resistance at $36Call Wall - dars.gov.et
Wolfe Research Initiates LB Pharmaceuticals(LBRX.US) With Buy Rating, Announces Target Price $45 - Moomoo
LBRX Initiated Coverage by Wolfe Research -- Rating Set to Outpe - GuruFocus
LB Pharmaceuticals Initiated at Outperform by Wolfe Research - Moomoo
Wolfe Research initiates LB Pharmaceuticals stock with outperform rating By Investing.com - Investing.com South Africa
Wolfe Research initiates LB Pharmaceuticals stock with outperform rating - Investing.com
LB Pharmaceuticals Inc (LBRX) Gains 4.83% as Stock Approaches Resistance at $35.10Early Entry Signals - dars.gov.et
LBRX Q1 2026 Earnings: EPS Beat Driven by Cost Control Amid Pre-Revenue StageShort-Term Outlook - dars.gov.et
LBRXLB Pharmaceuticals Inc Dividends - Finviz
LB Pharmaceuticals Inc. (LBRX) Maintains Buy Rating as Analyst Highlights LB-102 Potential - Yahoo Finance
5 Best Up and Coming Pharmaceutical Stocks to Buy Now - Insider Monkey
LB Pharmaceuticals names Christopher Zergebel as SVP By Investing.com - Investing.com South Africa
LB Pharmaceuticals names Christopher Zergebel as SVP - Investing.com
LB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations - GlobeNewswire
LB Pharmaceuticals appoints Christopher Zergebe... - Pluang
Total assets of LB Pharmaceuticals Inc – NASDAQ:LBRX - TradingView
LB Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:LBRX) - TradingView
LB Pharmaceuticals Inc (LBRX) Advances 2.19%, Nears Key Resistance at $34.25Market Cap Weight - dars.gov.et
LBRX Forecast — Price Target — Prediction for 2027 - TradingView
Lb Pharmaceuticals Inc Stock (LBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):